2 Best Biotech Stocks to Buy in August
Biotech stocks are often prone to highly inflated or highly deflated prices stemming from hyped news cycles. Between difficult-to-interpret news about a company's clinical-trial results and the sheer length of the drug-development cycle, some stocks spend months languishing because of the market's ire. But for investors with a long-term outlook, a biotech stock taking an unwarranted beating could be a great opportunity to buy in at a discount.
Both of the stocks I'll discuss today have had a rough year so far, performing worse than the market by a substantial margin. Furthermore, both lost out to the market over the last three years, potentially making conservative investors anxious. Despite their recent difficulties, however, these stocks have a few key value-investment factors in their favor, and there's reason to believe that the market will catch on soon enough.
Image source: Getty Images.
Source Fool.com
